Arrowhead Pharmaceuticals (ARWR) Current Ratio: History & Chart

Arrowhead Pharmaceuticals, Inc.(ARWR)

Biotechnology · Pasadena, CA

$60.79-1.57 (-2.51%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Pasadena, CA

711 employees

arrowheadpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher R. Anzalone

View full financials

ARWR Current Ratio Metrics

CURRENT RATIO

5.90

CURRENT RATIO AVG TTM

5.05

CURRENT RATIO AVG 3Y

5.43

CURRENT RATIO AVG 5Y

4.67

CURRENT RATIO AVG 10Y

4.72

CURRENT RATIO AVG 15Y

4.74

CURRENT RATIO AVG 20Y

4.88

CURRENT VS TTM AVG

+16.85%

CURRENT VS 3Y AVG

+8.64%

CURRENT VS 5Y AVG

+26.18%

CURRENT VS 10Y AVG

+24.85%

CURRENT VS 15Y AVG

+24.33%

CURRENT VS 20Y AVG

+20.78%

SECTOR MEDIAN · HEALTHCARE

3.34

median of 568 covered companies

CURRENT VS SECTOR MEDIAN

+76.35%

vs the sector median at left

NAME	MARKET CAP	CURRENT RATIO	TTM	3Y	5Y
Arrowhead Pharmaceuticals, Inc. (ARWR)	$8.56B	5.90	5.05	5.43	4.67
Kymera Therapeutics, Inc. (KYMR)vs ›	$8.70B	9.83	9.00	7.15	6.04
Caris Life Sciences, Inc. (CAI)vs ›	$8.54B	5.53	4.58	3.87	3.23
Axsome Therapeutics, Inc. (AXSM)vs ›	$8.83B	1.43	1.83	2.46	3.57
Oscar Health, Inc. (OSCR)vs ›	$8.36B	1.08	0.93	1.08	1.24
Insulet Corp. (PODD)vs ›	$9.35B	2.48	3.16	3.34	4.18
Bruker Corporation (BRKRP)vs ›	$9.10B	1.85	1.67	1.86	2.08
Bruker Corporation (BRKR)vs ›	$9.36B	1.85	1.67	1.86	2.08
Krystal Biotech, Inc. (KRYS)vs ›	$9.62B	8.32	8.62	12.07	13.88
Cytokinetics, Incorporated (CYTK)vs ›	$7.62B	6.66	5.35	6.55	8.14

NAME

MARKET CAP

CURRENT RATIO

TTM

Arrowhead Pharmaceuticals, Inc. (ARWR)

$8.56B

5.90

5.05

5.43

4.67

Kymera Therapeutics, Inc. (KYMR)vs ›

$8.70B

9.83

9.00

7.15

6.04

Caris Life Sciences, Inc. (CAI)vs ›

$8.54B

5.53

4.58

3.87

3.23

Axsome Therapeutics, Inc. (AXSM)vs ›

$8.83B

1.43

1.83

2.46

3.57

Oscar Health, Inc. (OSCR)vs ›

$8.36B

1.08

0.93

1.08

1.24

Insulet Corp. (PODD)vs ›

$9.35B

2.48

3.16

3.34

4.18

Bruker Corporation (BRKRP)vs ›

$9.10B

1.85

1.67

1.86

2.08

Bruker Corporation (BRKR)vs ›

$9.36B

1.85

1.67

1.86

2.08

Krystal Biotech, Inc. (KRYS)vs ›

$9.62B

8.32

8.62

12.07

13.88

Cytokinetics, Incorporated (CYTK)vs ›

$7.62B

6.66

5.35

6.55

8.14

Current Ratio FAQ

What is the current ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The current ratio for ARWR stock is 5.90.

Is Arrowhead Pharmaceuticals, Inc.'s current ratio high or low?

The current ratio of 5.90 is 26% above its 5-year average of 4.67, around the middle of its 5-year range (2.47–8.31).

What is the TTM average current ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The TTM average current ratio for ARWR stock is 5.05.

What is the 3Y average current ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 3Y average current ratio for ARWR stock is 5.43.

What is the 5Y average current ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 5Y average current ratio for ARWR stock is 4.67.

What is the 10Y average current ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 10Y average current ratio for ARWR stock is 4.72.

What is the 15Y average current ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 15Y average current ratio for ARWR stock is 4.74.

What is the 20Y average current ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 20Y average current ratio for ARWR stock is 4.88.

DATE	CURRENT RATIO
2026-06-30	5.90
2026-03-31	6.23
2025-12-31	3.38
2025-09-30	4.86
2025-06-30	4.87
2025-03-31	5.15
2024-12-31	6.09
2024-09-30	6.74
2024-06-30	4.65
2024-03-31	8.31
2023-12-31	3.73
2023-09-30	3.98
2023-06-30	6.69
2023-03-31	6.60
2022-12-31	4.11
2022-09-30	2.71
2022-06-30	3.37
2022-03-31	3.01
2021-12-31	2.47
2021-09-30	2.62
2021-06-30	2.69
2021-03-31	3.51
2020-12-31	12.90
2020-09-30	7.92
2020-06-30	7.37
2020-03-31	5.90
2019-12-31	6.89
2019-09-30	2.73
2019-06-30	2.81
2019-03-31	2.31
2018-12-31	1.85
2018-09-30	6.37
2018-06-30	8.68
2018-03-31	10.16
2017-12-31	3.87
2017-09-30	3.63
2017-06-30	3.83
2017-03-31	3.26
2016-12-31	2.87
2016-09-30	3.53
2016-06-30	3.34
2016-03-31	4.70
2015-12-31	6.67
2015-09-30	6.47
2015-06-30	12.03
2015-03-31	9.09
2014-12-31	11.49
2014-09-30	13.07
2014-06-30	19.81
2014-03-31	15.45
2013-12-31	8.47
2013-09-30	3.31
2013-06-30	5.15
2013-03-31	0.52
2012-12-31	1.00
2012-09-30	1.23
2012-06-30	1.02
2012-03-31	1.38
2011-12-31	1.81
2011-09-30	3.82
2011-06-30	3.26
2011-03-31	3.44
2010-12-31	1.40
2010-09-30	1.90
2010-06-30	1.97
2010-03-31	1.31
2009-12-31	1.61
2009-09-30	1.06
2009-06-30	0.81
2009-03-31	0.94
2008-12-31	1.86
2008-09-30	2.83
2008-06-30	5.69
2008-03-31	8.96
2007-12-31	11.48
2007-09-30	8.74
2007-06-30	10.92
2007-03-31	19.62
2006-12-31	28.37
2006-09-30	9.85
2006-06-30	18.13
2006-03-31	13.95
2005-12-31	13.40
2005-09-30	22.28
2005-06-30	25.85
2005-03-31	16.75
2004-12-31	20.78
2004-09-30	13.77
2004-06-30	29.32
2004-03-31	299.35
2003-12-31	104.56
2003-09-30	15.74
2003-06-30	0.01
2003-03-31	0.01
2002-12-31	0.01
2002-09-30	0.02

DATE

CURRENT RATIO

2026-06-30

5.90

2026-03-31

6.23

2025-12-31

3.38

2025-09-30

4.86

2025-06-30

4.87

2025-03-31

5.15

2024-12-31

6.09

2024-09-30

6.74

2024-06-30

4.65

2024-03-31

8.31

2023-12-31

3.73

2023-09-30

3.98

2023-06-30

6.69

2023-03-31

6.60

2022-12-31

4.11

2022-09-30

2.71

2022-06-30

3.37

2022-03-31

3.01

2021-12-31

2.47

2021-09-30

2.62

2021-06-30

2.69

2021-03-31

3.51

2020-12-31

12.90

2020-09-30

7.92

2020-06-30

7.37

2020-03-31

5.90

2019-12-31

6.89

2019-09-30

2.73

2019-06-30

2.81

2019-03-31

2.31

2018-12-31

1.85

2018-09-30

6.37

2018-06-30

8.68

2018-03-31

10.16

2017-12-31

3.87

2017-09-30

3.63

2017-06-30

3.83

2017-03-31

3.26

2016-12-31

2.87

2016-09-30

3.53

2016-06-30

3.34

2016-03-31

4.70

2015-12-31

6.67

2015-09-30

6.47

2015-06-30

12.03

2015-03-31

9.09

2014-12-31

11.49

2014-09-30

13.07

2014-06-30

19.81

2014-03-31

15.45

2013-12-31

8.47

2013-09-30

3.31

2013-06-30

5.15

2013-03-31

0.52

2012-12-31

1.00

2012-09-30

1.23

2012-06-30

1.02

2012-03-31

1.38

2011-12-31

1.81

2011-09-30

3.82

2011-06-30

3.26

2011-03-31

3.44

2010-12-31

1.40

2010-09-30

1.90

2010-06-30

1.97

2010-03-31

1.31

2009-12-31

1.61

2009-09-30

1.06

2009-06-30

0.81

2009-03-31

0.94

2008-12-31

1.86

2008-09-30

2.83

2008-06-30

5.69

2008-03-31

8.96

2007-12-31

11.48

2007-09-30

8.74

2007-06-30

10.92

2007-03-31

19.62

2006-12-31

28.37

2006-09-30

9.85

2006-06-30

18.13

2006-03-31

13.95

2005-12-31

13.40

2005-09-30

22.28

2005-06-30

25.85

2005-03-31

16.75

2004-12-31

20.78

2004-09-30

13.77

2004-06-30

29.32

2004-03-31

299.35

2003-12-31

104.56

2003-09-30

15.74

2003-06-30

0.01

2003-03-31

0.01

2002-12-31

0.01

2002-09-30

0.02

Current Ratio: 5.90

ARWR Current Ratio

ARWR Average Current Ratio Chart

ARWR Current vs Average Current Ratio Chart

ARWR Current Ratio Metrics

ARWR Competitors' Current Ratio

Liquidity Analysis

Current Ratio Formula & Definition

Current Ratio FAQ

ARWR Current Ratio History

Related Metrics